CD8A and prostate carcinoma: The most common tumor types enrolled were prostate cancer (17%), colorectal cancer (10%), sarcoma (10%), head and neck cancer (8%), and ovarian cancer (7%) in the CD8-low group, and head and neck cancer in three out of seven (43%) patients in the CD8-high group (Table 1).